ABEO (Abeona Therapeutics) GF Score: 31/100 (As of Jun. 27, 2026) — 33% Below Median


ABEO Abeona Therapeutics Inc ABEO
31 GF Score
Price $5.61
! 7 Warning Signs
View Full Analysis

What is Abeona Therapeutics GF Score?

Abeona Therapeutics ABEO +0.99% 31 GF Score is 31 as of Jun. 27, 2026, which is 33% below its 10-year median of 46.00. GuruFocus rates ABEO with a GF Score™ of 31/100. The stock has 7 warning signs investors should review.

Abeona Therapeutics has the GF Score of 31, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 5/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 7/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Abeona Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Abeona Therapeutics  (NAS:ABEO) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Abeona Therapeutics GF Score Related Terms

ABEO vs FATE, LCTX, BCYC: GF Score Comparison

For the Biotechnology subindustry, Abeona Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abeona Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's GF Score falls into.


ABEO
31GF Score
Abeona Therapeutics Inc ABEO
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 31 mean?
Abeona Therapeutics (ABEO) has a GF Score of 31 as of Jun. 27, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Abeona Therapeutics and its competitors. This is 33% below median its historical median of 46.00. Over the past decade, Abeona Therapeutics' GF Score has ranged from 29.00 to 70.00.
Is Abeona Therapeutics' GF Score too high?
Abeona Therapeutics' current GF Score of 31 is 33% below median its 10-year median of 46.00. Over the past 10 years, this metric has ranged from a low of 29.00 to a high of 70.00. Overall, Abeona Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' GF Score compare to FATE and LCTX?
Abeona Therapeutics' GF Score of 31 can be compared against companies in the Biotechnology industry. Historically, Abeona Therapeutics' own GF Score has ranged from 29.00 to 70.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current GF Score is 31, which is 33% below median its own 10-year median of 46.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Abeona Therapeutics (ABEO) has a current GF Score of 31. The current GF Score is 31, which is 33% below median its 10-year median of 46.00. Abeona Therapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Abeona Therapeutics (ABEO), the current GF Score is 31 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abeona Therapeutics Business Description

Other Exchanges 0H7R:UKPCJ:Germany
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
31GF Score

Get the complete analysis for ABEO

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.61
Price